• Publications
  • Influence
A multiinstitutional, concurrent chemoradiation trial of strontium‐89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone
Estramustine phosphate (EMP) and vinblastine have radiosensitizing properties and significant activity against hormone refractory prostate carcinoma. Strontium‐89 is a palliative agent that acts as aExpand
  • 62
  • 2
A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole
Warfarin is one of the most commonly used oral anticoagulants. Many medications have been shown to influence the prothrombin time in patients treated with warfarin by various mechanisms. We observedExpand
  • 15
Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer.
Clinically significant responses after withdrawal of flutamide in patients with hormone-refractory prostate cancer (HRPC) are well documented. Failure to recognize this syndrome of response resultsExpand
  • 6
  • PDF